Mesothelioma: A Killer Lurks in the Lungs

Data support new meningitis vaccine - US panel

Last Updated: 2004-09-22 15:46:15 -0400 (Reuters Health)

BETHESDA, Maryland (Reuters) - A panel of U.S. experts on Wednesday unanimously agreed that a new Sanofi-Aventis meningitis vaccine has been shown to be safe and effective, but said follow-up data were needed.

The new vaccine, called Menactra, is a longer-lasting meningitis vaccine that the company argued is safe and effective enough to give to children as young as 11. The vaccine is designed to protect them through their vulnerable college years.

The Food and Drug Administration usually follows the advice of its panels of outside experts when deciding whether to approve products.

"Post-marketing surveillance will be a critical part of this vaccine's future," said panel chair Dr. Gary Overturf, a pediatrics professor at the University of New Mexico Medical Center in Albuquerque.

Menactra aims to protect against one of three types of the infection that strikes the fluids surrounding the brain and spinal cord and can lead to seizures, brain damage, memory loss and even death.

The world's third-largest drug maker is seeking U.S. approval to market the vaccine for people ages 11 to 55.

While meningitis often occurs in young children, it also frequently crops up among older teenagers and young adults living in close quarters, including military recruits.

Menomune, the company's other vaccine for meningococcal meningitis, loses effectiveness after three to five years.

Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Back to Original Article : News You Can Use

Continue with:

Morphine-free poppy holds key to new pain-killers Last Updated: 2004-09-22 15:04:15 -0400 (Reuters Health) By Patricia Reaney LONDON (Reuters) - Australian scientists have discovered how a naturally morphine-free poppy blocks production of the narcotic, in a finding that could lead to the development of more effective drugs.

Early treatment ups survival after heart attack Last Updated: 2004-09-22 16:00:18 -0400 (Reuters Health) By Karla Gale NEW YORK (Reuters Health) - After a heart attack, treatment with angioplasty or bypass surgery during the initial hospital stay appears to improve survival compared with a more delayed, conservative approach, new research shows.

Don't let kids "play through pain," expert advises Last Updated: 2004-09-22 15:13:15 -0400 (Reuters Health) By Alison McCook NEW YORK (Reuters Health) - Children with persistent foot and ankle pain may have underlying injuries that could be worsened by further activity, according to a spokesperson for the American College of Foot and Ankle Surgeons.

Even mild kidney disease raises risk of death Last Updated: 2004-09-22 17:00:21 -0400 (Reuters Health) NEW YORK (Reuters Health) - Kidney disease need not be severe to cause an increased risk of death and cardiovascular disease, according to the findings from two studies published in The New England Journal of Medicine.

Supplements may reduce some chemotherapy side effects Last Updated: 2004-09-22 14:35:15 -0400 (Reuters Health) By Alison McCook NEW YORK (Reuters Health) - Breast cancer patients who take a multivitamin or extra vitamin E experience a smaller decrease in important immune cells, a common side effect of chemotherapy, new research suggests.

Back to News Page